Maraviroc Solution shortage
Maraviroc Solution is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Oct 5, 2026.
ViiV Healthcare is stopping maraviroc oral solution, and this change may be permanent. No other maker of this liquid form is listed as having supply right now.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Maraviroc Solution. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Jan 20, 2026Currently in shortage1 of 1 product affected.
-
Jan 20, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: ViiV Healthcare Company 📞 877-844-8872 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton (NDC 49702-260-55) | — | — | The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026. | — |
These rows are manufacturer reports to the FDA for Maraviroc Solution — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Maraviroc Solution? options further down this page.
Why is Maraviroc Solution in shortage?
ViiV Healthcare (through GSK) has let the FDA know that they plan to permanently stop distributing one specific version of Selzentry — the oral solution, which is the liquid form dosed at 20 mg/mL and packaged as a single 230 mL bottle per carton. Based on what was reported, they did not share a specific public reason for this decision. The anticipated last distribution date for this product is approximately August 1, 2026.
It's worth knowing that this report covers only this particular liquid kit from ViiV Healthcare/GSK. The FDA shortage database reflects what this one manufacturer filed, so it speaks only to this specific package and form being permanently stopped — not necessarily every form or version of maraviroc that exists.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Maraviroc Solution, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Maraviroc Solution?
Maraviroc oral solution (20 mg/mL, sold as Selzentry) is currently on the FDA shortage list. I'm sharing this so you know what's happening and what steps make sense next.
The one strength on this record — the 20 mg/mL Oral Solution Kit (a 230 mL bottle, one bottle per carton) — has no available source reported right now. There are no other strengths of this product still listed with supply. This record was filed by one manufacturer, ViiV Healthcare, and the product is marked "to be discontinued," with distribution expected to stop around August 1, 2026. Because this looks permanent for this maker, a conversation with your prescriber is the right next step.
Please keep these steps in mind:
- Do not stop, skip, or change doses on your own — keeping your treatment steady matters.
- Ask your pharmacy to check wholesalers and other suppliers; local stock can differ from national reports.
- Talk with your prescriber or pharmacist soon about a clinician-chosen plan, since this product is being discontinued.
- The manufacturer's contact number is listed on this page for reference; pharmacies usually handle those calls.
This is general information from national, manufacturer-reported FDA data and may not match your local pharmacy's stock. It isn't individual medical advice, so please let your care team guide your next move.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Maraviroc Solution?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Maraviroc Solution is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Alternative dosage forms of Maraviroc
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Selzentry | ViiV | 1 kit | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Identity & classification
Where does this data come from?
Other antiviral shortages
Maraviroc Solution shortage FAQs
Is Maraviroc Solution in shortage?
Which products are affected?
When will Maraviroc Solution be available again?
Can I still get Maraviroc somewhere?
What should I do if I take Maraviroc Solution?
Still have a question about the Maraviroc Solution shortage?
Ask a pharmacist about this shortage →View Maraviroc Solution on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.